<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03643627</url>
  </required_header>
  <id_info>
    <org_study_id>SYNT-101</org_study_id>
    <nct_id>NCT03643627</nct_id>
  </id_info>
  <brief_title>A Study of SYNT001 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1a, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study of SYNT001 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syntimmune, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Syntimmune, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to compare the safety, tolerability, pharmacokinetics (PK),
      pharmacodynamics (PD), and immunogenicity of an intravenous (IV) formulation of SYNT001. This
      is the first-in-human (FIH) study of SYNT001.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 17, 2016</start_date>
  <completion_date type="Actual">April 13, 2017</completion_date>
  <primary_completion_date type="Actual">April 13, 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assessment of safety data (counts and percentages of adverse events)</measure>
    <time_frame>Day 0 - Day 28</time_frame>
    <description>counts and percentages of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (serum concentration of SYNT001)</measure>
    <time_frame>Pre-dose and 0.08, 2, 4, 6, 8, 12, 16, 20, 24, 48, 72, and 120 hours post dose</time_frame>
    <description>serum concentration of SYNT001</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Days 1 (pre dose), 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 21 and 28</time_frame>
    <description>total serum IgG levels</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYNT001</intervention_name>
    <description>single IV infusion</description>
    <arm_group_label>1 mg/kg</arm_group_label>
    <arm_group_label>10 mg/kg</arm_group_label>
    <arm_group_label>3 mg/kg</arm_group_label>
    <arm_group_label>30 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        IInclusion Criteria:

        Subjects must meet the following criteria to be included:

          -  Healthy as determined by comprehensive clinical assessment and clinical laboratory
             investigations

          -  Body mass index 18.5 to 30.0 kg/m2

          -  Must use medically acceptable contraception

          -  Willingness to complete all study measurements and assessments in compliance with the
             protocol

        Exclusion Criteria:

        Subjects meeting any of the following criteria are to be excluded:

          -  Past or present disease that is judged by the investigator to have the potential to
             interfere with the study procedures, compromise safety or affect the PK evaluations

          -  Subject unable or unwilling to comply with the protocol

          -  Any exposure to an investigational drug within the 30 days prior to screening

          -  Use of any tobacco or nicotine-containing products

          -  Abuse of alcohol

          -  Positive drug test or history of drug abuse
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 21, 2018</study_first_submitted>
  <study_first_submitted_qc>August 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2018</study_first_posted>
  <last_update_submitted>August 23, 2018</last_update_submitted>
  <last_update_submitted_qc>August 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

